Evidence map›Paper›PMID 28627929›Full record

Trial reportClinical trials (London, England)2017

Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States.

Theresa Gamble, Bernard Branson, Deborah Donnell, H Irene Hall, Georgette King, Blayne Cutler, Shannon Hader, David Burns, Jason Leider, Angela Fulwood Wood and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical trials (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.Journal of acquired immune deficiency syndromes (1999) · 2019
    Article
  14. Article
  15. Article
  16. The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2019
    Article
  17. Expanding Hospital Human Immunodeficiency Virus Testing in the Bronx, New York and Washington, District of Columbia: Results From the HPTN 065 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  18. Article
  19. The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Theresa Gamble1 Science Facilitation Department, HPTN Leadership and Operations Center, FHI 360, Durham, NC, USA.
Bernard Branson2 Scientific Affairs, LLC, Atlanta, GA, USA.
Deborah Donnell3 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
H Irene Hall4 Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Georgette King1 Science Facilitation Department, HPTN Leadership and Operations Center, FHI 360, Durham, NC, USA.
Blayne Cutler5 Public Health Foundation Enterprises, La Puente, CA, USA.
Shannon Hader6 DC Department of Health, HIV/AIDS, Hepatitis, STD and TB Administration, Washington, DC, USA.
David Burns7 Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Jason Leider8 Albert Einstein College of Medicine, New York, NY, USA.
Angela Fulwood Wood9 Family and Medical Counseling Service, Inc., Washington, DC, USA.
Kevin G Volpp10 Center for Health Incentives and Behavioral Economics; Perelman School of Medicine and the Wharton School, University of Pennsylvania, Philadelphia, PA, USA.
Kate Buchacz4 Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Wafaa M El-Sadr11 ICAP at Columbia University, Mailman School of Public Health, New York, NY, USA.
HPTN 065 Study Team

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619
6 · The paper itself

Abstract

Background/Aims HIV continues to be a major public health threat in the United States, and mathematical modeling has demonstrated that the universal effective use of antiretroviral therapy among all HIV-positive individuals (i.e. the "test and treat" approach) has the potential to control HIV. However, to accomplish this, all the steps that define the HIV care continuum must be achieved at high levels, including HIV testing and diagnosis, linkage to and retention in clinical care, antiretroviral medication initiation, and adherence to achieve and maintain viral suppression. The HPTN 065 (Test, Link-to-Care Plus Treat [TLC-Plus]) study was designed to determine the feasibility of the "test and treat" approach in the United States. Methods HPTN 065 was conducted in two intervention communities, Bronx, NY, and Washington, DC, along with four non-intervention communities, Chicago, IL; Houston, TX; Miami, FL; and Philadelphia, PA. The study consisted of five components: (1) exploring the feasibility of expanded HIV testing via social mobilization and the universal offer of testing in hospital settings, (2) evaluating the effectiveness of financial incentives to increase linkage to care, (3) evaluating the effectiveness of financial incentives to increase viral suppression, (4) evaluating the effectiveness of a computer-delivered intervention to decrease risk behavior in HIV-positive patients in healthcare settings, and (5) administering provider and patient surveys to assess knowledge and attitudes regarding the use of antiretroviral therapy for prevention and the use of financial incentives to improve health outcomes. The study used observational cohorts, cluster and individual randomization, and made novel use of the existing national HIV surveillance data infrastructure. All components were developed with input from a community advisory board, and pragmatic methods were used to implement and assess the outcomes for each study component. Results A total of 76 sites in Washington, DC, and the Bronx, NY, participated in the study: 37 HIV test sites, including 16 hospitals, and 39 HIV care sites. Between September 2010 and December 2014, all study components were successfully implemented at these sites and resulted in valid outcomes. Our pragmatic approach to the study design, implementation, and the assessment of study outcomes allowed the study to be conducted within established programmatic structures and processes. In addition, it was successfully layered on the ongoing standard of care and existing data infrastructure without disrupting health services. Conclusion The HPTN 065 study demonstrated the feasibility of implementing and evaluating a multi-component "test and treat" trial that included a large number of community sites and involved pragmatic approaches to study implementation and evaluation.

Indexed as

Anti-Retroviral AgentsContinuity of Patient CareFeasibility StudiesFemaleHIV InfectionsHumansMaleMass ScreeningMedication AdherencePilot ProjectsProspective StudiesResearch DesignSurveys and QuestionnairesUnited StatesAnti-Retroviral Agentsexpanded HIV testingfinancial incentivesHIV viral suppressionlinkage to HIV carepragmatic clinical trial“Test and treat” approach for HIV prevention

Identifiers

PMID28627929
PMCPMC5639958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.